Inflammatory Myofibroblastic Tumor After Treatment of Wilms Tumor in a 6-Year-Old Boy: A Case Report and Literature Review

Liu, Yunpeng; Han, Wei; He, Lin; Zheng, Wentao; Zhang, Weiping

doi:10.1016/j.urology.2020.11.012

Cited by 5 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whole transcriptome sequencing showed complete discordance in gene expression between adrenal NB specimens and liver IMT specimens, this transcriptomic level analysis again validated the non-homologous nature of the patient's two successive tumors. Genetic studies have similarly shown that rearrangement of the ALK gene may contribute to tumorigenesis, suggesting that IMT is likely to occur as a tumor entity and is not a reactive progression due to a particular disease [ 9 ]. Our immunohistochemistry results also showed strong positivity for ALK, which can be used to differentiate from NB.…”

Section: Discussionmentioning

confidence: 99%

“…Another study reported malignant gastrointestinal neuroectodermal tumour as the second primary malignant tumor after pediatric NB treatment [ 8 ]. IMT is a rare inert tumor that has been less frequently reported as a second tumor occurring after treatment of malignancy in pediatric patients, with cases of IMT occurring after treatment of pediatric nephroblastoma reported [ 9 ]. Characterized by spindle cell proliferation and inflammatory cell infiltration, IMT is an intermediate state tumor with malignant potential, and therefore should be given adequate attention when it appears as a second tumor [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory myofibroblastic tumor of the liver after adrenal neuroblastoma surgery: a case report

Shen,

Liu,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

A boy aged 55 months was diagnosed with stage IV Neuroblastoma (NB) of the right adrenal gland 2 years ago. Preoperative chemotherapy was given and he was then treated with retroperitoneal tumor resection and lymph node dissection. After surgery, the children were transferred to the Hemato-Oncology Department for chemotherapy according to the high-risk group NB, with outpatient follow-up every 6 months. In the second postoperative year, abdominal computed tomography (CT) scan revealed a rounded hypodense area in the upper part of the right posterior lobe of the liver, with marked inhomogeneous enhancement in the venous phase after enhancement, which was surgically resected, and postoperative pathology confirmed inflammatory myofibroblastic tumor (IMT) of liver. The patient was not given any special treatment after surgery. In this study, whole transcriptome sequencing was performed on the postoperative specimen of adrenal NB and the specimen of IMT of liver. This unusual case emphasizes the need for close monitoring of second tumor development in NB survivors even in the absence of known predisposing factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inflammatory myofibroblastic tumor of the liver after adrenal neuroblastoma surgery: a case report

Shen,

Liu,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…A literature review did not show a clear correlation with radiation. However, there have been case reports of pediatric patients who presented with pulmonary IMT after undergoing treatment for Wilms tumor [ 5 , 6 ]. Although the occurrence of the two tumors may have been a coincidence in this patient, there may be a causal link.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumor After Receiving Treatment for Non-small Cell Carcinoma

Parker,

Singanallur,

Faiek

et al. 2024

Cureus

View full text Add to dashboard Cite

Inflammatory pseudotumor encompasses a spectrum of both neoplastic and non-neoplastic conditions characterized by a histological pattern featuring a proliferation of cytologically bland spindle cells, accompanied by a prominent chronic inflammatory infiltrate. Within this spectrum, inflammatory myofibroblastic tumor (IMT) has emerged as a distinct entity over the past two decades, marked by unique clinical, pathological, and molecular characteristics. Typically affecting the visceral soft tissues of children and adolescents, IMT exhibits a propensity for local recurrence while posing a minimal risk of distant metastasis. They are extremely rare in adults, constituting less than 1% of adult lung tumors. Our patient, a 63-year-old female, has an intricate medical background, encompassing chronic obstructive pulmonary disease (COPD), a previous history of smoking (35 pack-years, quit a year before admission), coronary artery disease, non-obstructive hypertrophic cardiomyopathy, and obstructive sleep apnea. Presenting with a diagnostic dilemma, she recently received treatment for non-small cell carcinoma with radiation therapy, which has evolved into a swiftly advancing case of IMT.

show abstract

“…Spleen tumors, among other infantile forms, have been reported to cause growth restriction in infants [23]. A case of coexistence of Wilms' tumor with IMT has also been reported, which raises the question of whether these tumors share a common pathogenesis or whether IMT could have been induced by treatment of Wilms' tumor [24]. IMT development occurs at all ages with most patients diagnosed below 40 years of age [25][26][27], although it can develop as late as the eighth decade of life [28,29].…”

Section: Epidemiologymentioning

confidence: 99%

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

CHMIEL,

SłOWIKOWSKA,

BANASZEK

et al. 2024

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.

show abstract

Inflammatory Myofibroblastic Tumor After Treatment of Wilms Tumor in a 6-Year-Old Boy: A Case Report and Literature Review

Cited by 5 publications

References 14 publications

Inflammatory myofibroblastic tumor of the liver after adrenal neuroblastoma surgery: a case report

Inflammatory myofibroblastic tumor of the liver after adrenal neuroblastoma surgery: a case report

Inflammatory Myofibroblastic Tumor After Receiving Treatment for Non-small Cell Carcinoma

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

Contact Info

Product

Resources

About